200mg Cannabidiol by capsules twice daily ( DrugBank: Cannabidiol )


1 disease
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis1

46. Malignant rheumatoid arthritis


Clinical trials : 4,325 Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04911127
(ClinicalTrials.gov)
October 5, 202114/5/2021Therapeutic Response of Cannabidiol in Rheumatoid ArthritisRandomized, Double Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Cannabidiol (CBD) in Moderate to Severe Rheumatoid ArthritisRheumatoid Arthritis;CannabisDrug: 200mg Cannabidiol by capsules twice daily;Drug: 400mg Cannabidiol by capsules twice daily;Drug: Placebo capsulesUniversity of California, Los AngelesNULLRecruiting18 YearsN/AAll60Phase 1/Phase 2United States